The treatment of HER2-positive breast cancer is being greatly enhanced by ADCs such as trastuzumab deruxtecan, ARX788, and ZW49 and are proficiently utilized to deliver the potent cytotoxic drugs by using mAbs with low off-target toxicities. Here, ERBB2 is linked to breast carcinoma.